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BACKGROUND: A provocative finding from several
double-blind clinical trials has been the association
between greater adherence to placebo study medication
and better health outcomes. We used data from the
Studies of Left Ventricular Dysfunction (SOLVD) Treat-
ment Trial (SOLVD-TT) and the SOLVD Prevention Trial
(SOLVD-PT) to examine whether such associations
could be validated and to examine several sources of
bias and potential confounding.
METHODS: Survival analytic methods were used to
estimate the association between placebo adherence
and several health outcomes, employing a number of
modeling techniques to test for the existence of alter-
native explanations for the association. Higher adher-
ence was defined as having taken ≥75% of prescribed
study medication.
RESULTS: Higher placebo adherence was associated
with improved overall survival in both SOLVD-TT and
SOLVD-PT [hazard ratio (HR)=0.52, 95% confidence
interval (CI): 0.35 to 0.79 and HR=0.52, 95%CI: 0.38
to 0.71, respectively]. Associations were similar for fatal
or non-fatal cardiovascular or coronary heart disease
events. Adjustment for both modifiable and non-modi-
fiable cardiac risk factors (including age, gender, diabe-
tes, blood pressure, smoking, weight, alcohol use, and
levels of education) had minimal effect on the strength
of the association. Little evidence of bias was found as
an explanation for this relationship.
CONCLUSIONS: In these two trials, better adherence to
placebo was associated with markedly superior health
outcomes, including total in-study mortality and inci-
dent cardiovascular events. No important confounders
were identified. These data suggest there may exist
strong but unrecognized determinants of health out-
comes for which placebo adherence is a marker.
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INTRODUCTION
It is not surprising that better adherence to effective medica-
tion results in better health outcomes
1,2. A provocative finding
from the analysis of double-blind clinical trials, however, has
been the discovery of a strong association between better
adherence to placebo medication and improved survival. Post-
hoc analyses of several clinical trials have found that placebo-
allocated participants who were relatively more adherent had
markedly improved survival compared to those who were
relatively less adherent, with reductions in mortality ranging
from approximately 40% to 75%
3–11.
Why this should be so remains a mystery. The simplest
explanation is that the published data represent only a select
group of positive studies, rendering the published literature
biased toward identifying this association. Other potential
explanations include the possibility that medication adherence
is only a proxy for healthier lifestyle and behaviors, that
adherence to placebo is associated with adherence to life-
prolonging medications, or that the association is confounded
by participants who become ill and who are, therefore, bothmore
likely to become non-adherent and more likely to die because of
their illness (i.e., protopathic bias). Most published studies have
examined potential confounding by a limited number of covari-
ates, but have not thoroughly examined these other explana-
tions,sothe existenceofthis associationis uncertainand, iftrue,
its explanation remains largely unexplored.
The strength and apparent consistency of this relationship
merit further investigation. Should the presence of the associ-
ation be validated, the clinical and public-health implications
are profound, given the extraordinarily strong protection asso-
ciated with adherence to placebo. Understanding why medica-
tion adherence itself, independent of the medication's efficacy,
would be associated with such markedly improved health
outcomes could shed new light on powerful determinants of
health and longevity. To examine this issue more carefully, we
conducted a secondary data analysis of two large placebo-
controlled clinical trials for which no prior examinations of this
association had been performed; these analyses are part of a
larger multi-study investigation of this remarkable relationship.
METHODS
Original Study and Data
We used data from the Studies Of Left Ventricular Dysfunction
(SOLVD)
12–14, a pair of large, double-blind, placebo-controlled
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1275randomized clinical trials of enalapril in patients with conges-
tive heart failure (CHF). Participants had a cardiac ejection
fraction <35% and were randomized into one of two separate
trials that followed the same treatment protocol: those who
were symptomatic were entered into the SOLVD Treatment
Trial (SOLVD-TT)
13, and those without symptoms were en-
rolled in the SOLVD Prevention Trial (SOLVD-PT)
14. Partici-
pants were titrated to a dose of 10 mg of enalapril twice daily
and followed every 4 months for a mean 37 to 41 months for
the primary endpoint of all-cause mortality. Enalapril reduced
mortality in both trials, though the effect was statistically
significant only in the Treatment Trial
13,14. Both studies found
significantly fewer CHF-related hospitalizations in enalapril-
allocated participants, and the Prevention Trial demonstrated
a significant reduction in the incidence of symptomatic
CHF
13,14. Data for our analyses were obtained from the
National Heart, Lung, and Blood Institute Data Repository of
Epidemiology and Clinical Trials
15.
Analytic Methods
The primary objective of these analyses was to obtain an
unbiased and unconfounded estimateofthe association between
adherence to study medication and total in-study mortality
among those participants randomized to the placebo group in
both SOLVD studies. Secondary objectives included assessment
of the association between placebo adherence and cause-specific
mortality, including coronary heart disease (CHD) mortality, all
cardiovascular disease (CVD) mortality (CHD, CHF, and stroke),
and non-CVD mortality; the incidence of fatal or non-fatal CHD
and CVD events was also investigated. We also examined several
potential sources of bias and confounding.
We used survival analysis to assess the effects of placebo
adherence
16. We first generated Kaplan-Meier curves stratified
by adherence and compared the adherence strata using log-
rank tests. We used Cox proportional hazards models to obtain
adjusted estimates of adherence effects and tested the propor-
tionality assumption in the primary analysis using an interac-
tion term containing the product of adherence and time
16.
Covariate adjustments included a pre-defined set of variables
that included demographics, modifiable and non-modifiable risk
factors and education (as the only psychosocial variable avail-
able). Baseline values of covariates were used for adjustment, as
we did not have longitudinal measurements for most covariates.
All analyses were performed with SAS v. 9.1
17.
The primary definition of placebo adherence was having
taken at least 75% of prescribed placebo study medication. We
also conducted sensitivity analyses in which we varied the cutoff
point for higher adherence from 50% to 95%. For most analyses,
adherence was treated as a fixed binary variable, defined as the
total number of pills taken by a participant over each interval, as
determined by pill counts, divided by the total number of pills
that should have been taken during that interval; these
percentages were then averaged over all intervals (i.e., the total
mean adherence). For supplementary analyses, we calculated
adherence as a cumulative variable using pill counts for the
entire interval from baseline up to the most recent visit before
each outcome event (i.e., at the determination of the survival
probability at each failure time, adherence was re-calculated as
the total placebo adherence up to the time of the event; this
definition is termed the cumulative mean adherence). In another
set of analyses, we also treated adherence as a simple time-
dependent adherence variable using only the single adherence
value for the most recent interval prior to each outcome event.
Finally, one set of models used total mean adherence as a
continuous variable.
Some participants had individual study visits in which raw
adherence measurements exceeded 100% (participants received
more study medication than needed for full adherence at the
following visit). Percentages slightly greater than 100% were
likely due to having lost or taken a few extra doses. Larger
adherence values more likely arose from counting or data-entry
errors. Accordingly, values between 101% and 125% were
recoded as 100%, while values greater than 125% were set to
missing for that visit.
In order to examine the possibility that both reduced
adherence and mortality were due to some other serious,
ultimately fatal illness, we repeated the analyses for total
mortality after deleting each participant's last adherence mea-
surement and last two measurements (these procedures reduce
the effect of the adherence measurements in the 4 to 8 months
before a participant's death), to test if the association attenuated.
Wealsorepeatedtheproportionalhazardsmodels,usingalagged
adherence variable, which also diminishes the influence of the
ultimate and penultimate adherence measurements; this proce-
dure was conducted on both the cumulative mean-adherence
variable and the time-dependent adherence variable. The time-
dependent adherence definition would be the most sensitive to
the lagged-variable procedure, since it is based on a single
measurement (not averaged over several measurements) and
provides the most sensitive test of the possibility of protopathic
bias.
RESULTS
SOLVD Treatment Trial
Among the placebo-allocated participants, 98 out of 1,255
(7.8%) took less than 75% of their prescribed study medica-
tion, and the distribution of adherence values was highly
Figure 1. Distribution of total mean adherence levels among
placebo-allocated participants in the SOLVD studies.
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these were set to missing. No individuals were lost due to this
data step. Other than small differences in the distribution of
race, there were no significant differences in baseline char-
acteristics between higher and lower adherent participants
(Table 1). Overall, there were 491 in-study deaths (39.1% of
randomized participants), with the great majority being due to
cardiovascular causes (90.2% of all deaths; Table 2).
More adherent participants had significantly lower total
mortality relative to less adherent participants (HR=0.52,
95% CI: 0.38 to 0.71; Table 2,a n dF i g .2a). The association
was also found to be statistically significant for CVD mortality
(which included CHF-related mortality), but not for CHD or
non-CVD-related deaths, though the numbers of outcomes in
t h e s et w os u b g r o u p sw e r es m a l l .M o r ea d h e r e n tp a r t i c i p a n t s
were also less likely to suffer either an incident CVD or CHD
event, though the latter was of borderline significance
(Table 2). The association between placebo adherence and
total mortality persisted when total mean adherence was
treated as a continuous measurement with HR = 0.89 (95%
CI: 0.84 to 0.95) for every 10% increase in adherence. The
association was similar when adherence was used as a time-
dependent covariate (HR=0.50, 95% CI: 0.38 to 0.66). When
adherence was calculated as a cumulative variable (i.e., each
participant's adherence was re-calculated at each visit using
measurements only up to that point), the association
remained significant (HR=0.58, 95% CI: 0.43 to 0.79).
Table 1. Baseline Characteristics of Placebo-allocated Participants in Both SOLVD Studies, Overall and by Adherence Level
Baseline characteristic SOLVD-Treatment SOLVD-Prevention
Higher adherence
a
N=1,157
Lower adherence
N=98
p-value Higher adherence N=1,951 Lower adherence
N=141
p-value
Demographics
Age (years; mean, SD) 60.6 (9.6) 59.8 (10.8) 0.30 58.9 (10.3) 55.4 (12.2) <0.001
Gender, N (%)
M 918 (79) 85 (87) 0.08 1,737 (89) 121 (86) 0.24
F 239 (21) 13 (13) 214 (11) 20 (14)
Race, N (%)
White 962 (82) 59 (75) 0.02 1,713 (88) 101 (73) <0.001
African-American 162 (14) 18 (23) 171 (9) 34 (24)
Other 51 (4) 2 (3) 65 (3) 6 (4)
Married/partnered (%)
b 15 (79) 177 (74) 0.62 868 (76) 53 (74) 0.60
Education
Less than high school 500 (46) 37 (44) 0.90 416 (36) 27 (35) 0.88
High school graduate 360 (33) 28 (33) 379 (33) 28 (36)
Greater than high school 224 (21) 19 (23) 347 (30) 23 (29)
Clinical characteristics
Systolic blood pressure,
mmHg (mean, SD)
124.8 (17.2) 122.8 (18.3) 0.37 125.7 (16.6) 123.8 (18.1) 0.12
Concurrent medications
(mean, SD)
5.4 (1.9) 5.8 (1.9) 0.58 3.1 (2.0) 3.1 (2.1) 0.30
Diabetes (%) 310 (27) 22 (23) 0.38 288 (15) 22 (21) 0.06
Weight, kg (mean, SD) 79.5 (16.8) 80.9 (16.0) 0.53 81.7 (14.3) 82.1 (14.7) 0.62
Current smoker (%)
Never 280 (24) 19 (20) 0.43 411 (21) 22 (16) 0.05
Current 245 (21) 25 (26) 461 (24) 45 (32)
Former 632 (55) 53 (55) 1,079 (55) 74 (52)
Avg alcohol in past 2 years (%)
None 693 (60) 48 (52) 0.25 992 (52) 65 (47) 0.55
1–2 Drinks/day 396 (34) 39 (42) 793 (41) 63 (46)
>2 Drinks/day 59 (5) 6 (6) 139 (7) 9 (7)
a“Higher adherence” defined as ≥75% total in-study placebo medication adherence
bAvailable on only one-fifth of SOLVD-TT participants and half of SOLVD-PT participants
Table 2. Unadjusted Hazard Ratios for Association of Placebo
Adherence with Mortality and Incident Events in the SOLVD
Treatment Trial
Lower
adherent
participants
(N=98)
Higher
adherent
a
participants
(N=1,157)
Outcome No. events No. events HR 95% CI
Total
mortality
45 446 0.52 0.38–0.71
CVD
mortality
41 402 0.52 0.38–0.72
Non-CVD
mortality
4 44 0.53 0.19–1.48
CHD
mortality
3 59 0.96 0.30–3.08
Incident CVD
events (fatal and
non-fatal)
85 855 0.46 0.36–0.57
Incident CHD
events (fatal and
non-fatal)
11 130 0.54 0.29–1.00
Legend:
CHD=Coronary heart disease
CVD=Cardiovascular disease
CI=Confidence interval
a“Higher adherent” defined as≥75% total in-study placebo medication
adherence
Significant differences (p<0.05) indicated in bold type
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arbitrary, we conducted a sensitivity analysis on the placebo
adherence-mortality association at different cutoff points of
adherence. The value of the total mean adherence for which
the association with mortality was strongest was at a cutoff
point of 55% adherence (HR=0.42, 95% CI: 0.27 to 0.66).
Adjustment for potential confounders (demographics,
modifiable and non-modifiable CVD risk factors, and educa-
tion) did not result in a meaningful change in the association
for any outcome (Table 3).
Several analyses were conducted to examine the possibility
that the association between placebo adherence and mortal-
ity was the result of a serious and ultimately fatal illness,
Table 3. Adjusted Hazard Ratios (and 95% Confidence Intervals) for Association of Placebo Adherence with Mortality and Incident Events in
the SOLVD Treatment Trial
Outcome Non-modifiable risk factors
a Modifiable risk factors
b All risk factors
c Psychosocial
measures
d
All covariates
e
Mortality
Total mortality 0.54 (0.39, 0.74) 0.53 (0.38, 0.74) 0.56 (0.40, 0.77) 0.55(0.39, 0.78) 0.58 (0.41, 0.83)
CVD 0.54 (0.39, 0.75) 0.54 (0.38, 0.76) 0.56 (0.40, 0.79) 0.55 (0.38, 0.78) 0.58 (0.40, 0.84)
Non-CVD 0.56 (0.20, 1.58) 0.45 (0.16, 1.27) 0.51 (0.18, 1.44) 0.63 (0.19, 2.03) 0.61 (0.19, 2.01)
CHD 0.92 (0.29, 2.97) 0.85 (0.26, 2.72) 0.82 (0.25, 2.64) 0.82 (0.26, 2.63) 0.74 (0.23, 2.40)
Morbidity
Incident CVD events (fatal
and non-fatal)
0.57 (0.45, 0.72) 0.56 (0.44, 0.70) 0.56 (0.45, 0.71) 0.55 (0.43, 0.70) 0.54 (0.42, 0.69)
Incident CHD events (fatal
and non-fatal)
0.84 (0.45, 1.55) 0.81 (0.43, 1.55) 0.84 (0.44, 1.60) 1.02 (0.50, 2.08) 0.93 (0.46, 1.92)
Legend:
CHD=Coronary heart disease
CVD=Cardiovascular disease
aNon-modifiable risk factors: age, sex, race
bModifiable risk factors: diabetes, alcohol, smoking, SBP, weight
cAll risk factors: age, sex, race, diabetes, alcohol, smoking, SBP, weight
dPsychosocial measures: education
eAll covariates: all of the above
Significant differences (p<0.05) indicated in bold type
Figure 2. a Kaplan-Meier curves of cumulative survival for higher
adherent (solid line) and lower adherent (dashed line) placebo-
allocated study participants in the SOLVD Treatment Trial. b
Kaplan-Meier curves of cumulative survival for higher adherent
(solid line) and lower adherent (dashed line) placebo-allocated
study participants in the SOLVD Prevention Trial.
Table 4. Unadjusted Hazard Ratios for Association of Placebo
Adherence with Mortality and Incident Events in the SOLVD
Prevention Trial
Lower
adherent
participants
(N=141)
Higher
adherent
a
participants
(N=1,951)
Outcome No. events No events HR 95% CI
Total mortality 25 292 0.52 0.35–0.79
CVD mortality 20 261 0.59 0.37–0.93
Non-CVD mortality 5 31 0.27 0.11–0.70
CHD mortality 4 47 0.49 0.18–1.37
Incident CVD
events (fatal and
non-fatal)
84 980 0.49 0.39–0.61
Incident CHD
events (fatal and
non-fatal)
17 177 0.42 0.26–0.70
Legend:
CHD=Coronary heart disease
CVD=Cardiovascular disease
CI=Confidence interval
a“Higher adherent” defined as≥75% total in-study placebo medication
adherence
Significant differences (p<0.05) indicated in bold type
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adherence in the months prior to the participant's death.
First, we estimated the association after eliminating the last
and the last two adherence measurements; these procedures
resulted in some attenuation in the association (HR=0.75,
95% CI: 0.49 to 1.15 and HR=0.77, 95% CI: 0.49 to 1.22,
respectively). Next, we lagged the adherence variable in the
survival models with cumulative mean adherence by one
measurement (HR=0.88, 95% CI: 0.57 to 1.35) and by two
measurements (HR=0.84, 95% CI: 0.53 to 1.34). However,
the estimated effect of recent adherence as a time-dependent
covariate was unaffected when it was calculated using data
from the second (HR=0.54, 95% CI: 0.34 to 0.85) or third
(HR=0.60, 95% CI: 0.36 to 0.98) most recent visit before
each outcome event, rather than the most recent visit, as in
the primary analysis.
SOLVD Prevention Trial
Among the 2,092 placebo-allocated participants in the SOLVD
Prevention Trial, 141 (6.7%) were "lower adherent," and these
participants tended to be slightly younger, current smokers, of
African-American race, and diabetic (Table 1). Only 2% of visit
adherence values were set to missing because they exceeded
125% adherence. Mortality was lower in the Prevention Trial
(14.8%), with a distribution in causes of death similar to that
in the Treatment Trial.
The hazard ratio for total mean placebo adherence and all-
cause mortality was identical to that in SOLVD-TT (HR=0.52,
95% CI: 0.35 to 0.79, Table 4 and Fig. 2b). Results were more
consistent and significant across all causes of death com-
pared to the Treatment Trial: with the exception of CHD
mortality (in which the association was strong but not
statistically significant), more adherent participants showed
substantially greater survival (Table 4). Results were also
similar regardless of whether adherence was treated as a
cumulative variable (HR=0.58, 95% CI: 0.39 to 0.88), a time-
dependent variable (HR=0.53, 95% CI: 0.36 to 0.77), or a
continuous variable (HR=0.90, 95% CI: 0.83 to 0.98 for each
10% increase in adherence). In the sensitivity analysis of the
optimal adherence cutpoint, the association between placebo
adherence and mortality was strongest using a cutoff point
for adherence of 60% (HR=0.42, 95% CI: 0.23 to 0.74).
As in the Treatment Trial, multivariable adjustment had little
effect on the results. The association between placebo adherence
and mortality was similar in the bivariate and fully adjusted
models for all outcomes except non-CVD mortality, for which
adjustment caused substantial attenuation (Table 5).
The Prevention Trial analyses did not support the concept that
other serious illness was responsible for both the lower adher-
ence and higher mortality. Unlike the Treatment Trial analyses,
the association remained significant after dropping the final total
mean adherence measurement (HR=0.61, 95% CI: 0.38 to 0.96)
or the final two adherence measurements (HR=0.54, 95% CI:
0.34 to 0.88) in the models using total mean adherence. Results
were similar in the models using adherence as a cumulative
mean variable (HR=0.55, 95% CI: 0.34 to 0.87 with a single lag
and HR=0.49, 95% CI: 0.30 to 0.79 with two lags in the
adherence variable). Finally, the association was also essentially
unchanged when estimated using adherence as a time-depen-
dent variable and using the second (HR=0.54, 95% CI: 0.35 to
0.86) or third (HR=0.59 95% CI: 0.36 to 0.98) most recent visit.
DISCUSSION
It is surprising that better adherence to placebo should be
associated with reduced mortality, since placebo, by definition,
has no specific biologic or disease-modifying activity. There-
fore, placebo adherence must be a marker for some other
factors responsible for this extraordinary survival advantage,
but what those factors might be remains a mystery. Adjust-
ment for numerous available potential confounders did not
appreciably attenuate the association, suggesting that the
placebo adherence-mortality association is independent of
these known risk factors. In addition, the association appeared
to be generally present across all outcomes and for both
mortality and incident events.
Table 5. Adjusted Hazard Ratios (and 95% Confidence Intervals) for Association of Placebo Adherence with Mortality and Incident Events in
the SOLVD Prevention Trial
Outcome Non-modifiable risk
factors
a
Modifiable risk
factors
b
All risk factors
c Psychosocial
measures
d
All covariates
e
Mortality
Total mortality 0.54 (0.35, 0.81) 0.56 (0.36, 0.86) 0.57 (0.37, 0.89) 0.49 (0.31, 0.79) 0.52 (0.31, 0.86)
CVD 0.59 (0.37, 0.94) 0.60 (0.37, 0.96) 0.60 (0.37, 0.98) 0.53 (0.31, 0.88) 0.51 (0.30, 0.87)
Non-CVD 0.31 (0.11, 0.70) 0.37 (0.13, 1.05) 0.42 (0.14, 1.28) 0.31 (0.09, 1.04) 0.60 (0.13, 2.83)
CHD 0.49 (0.17, 1.39) 0.51 (0.18, 1.44) 0.50 (0.17, 1.44) 0.40 (0.14, 1.12) 0.38 (0.13, 1.14)
Morbidity
Incident CVD events (fatal and non-fatal) 0.70 (0.55, 0.88) 0.73 (0.58, 0.92) 0.71 (0.56, 0.90) 0.67 (0.51, 0.89) 0.67 (0.50, 0.89)
Incident CHD events (fatal and non-fatal) 0.65 (0.39, 1.08) 0.75 (0.45, 1.26) 0.69 (0.41, 1.16) 0.88 (0.45, 1.74) 0.87 (0.44, 1.74)
Legend:
CHD=Coronary heart disease
CVD=Cardiovascular disease
aNon-modifiable risk factors: age, sex, race
bModifiable risk factors: diabetes, alcohol, smoking, SBP, weight
cAll risk factors: age, sex, race, diabetes, alcohol, smoking, SBP, weight
dPsychosocial measures: education
eAll covariates: all of the above
Significant differences (p<0.05) indicated in bold type
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merely a marker for adherence to other life-prolonging medica-
tions, and this possibility cannot be examined with the
available data.
Another possibility is that some patients developed fatal
illnesses with a prodrome (such as cancer), which could be
responsible for both the participant's death and a reduction in
their adherence to study medication. We investigated this
possibility in several ways. We reasoned that, if the placebo
adherence-mortality association was due to a decline in
adherence just prior to a participant's death, then dropping
the last one or two adherence measurements (or lagging the
adherence variable by one or two visits) should result in
substantial attenuation of the association. In fact, these
procedures did result in some attenuation in the Treatment
Trial, but not in the Prevention Trial results. Why these results
differ is not entirely clear. While the mortality was higher in the
Treatment Trial, there was sufficient power in the Prevention
Trial such that all results retained statistical significance and
the widths of the confidence intervals for SOLVD-PT were
smaller than for SOLVD-TT. Finally, when we treated adher-
ence as a simple time-dependent covariate, the association
and its statistical significance remained essentially unchanged
in both trials after lagging the adherence variable (this was the
adherence measure that we hypothesized should be the most
sensitive to protopathic bias as it is less influenced by prior
adherence measurements). Taken together, these analyses
suggest that, in the SOLVD trials, there was little support for
the potential explanation that the placebo adherence-mortality
association is a simple artifact of the presence of some other
serious illness, though the inconsistency in the results
between the SOLVD Treatment and Prevention studies merit
further study in other datasets.
It is noteworthy that we had no prior knowledge of these
results and that we resolved a priori to publish these findings
regardless of the outcome. Most prior published studies are
consistent with our findings, though potential publication bias
must be considered. Study of more datasets, as part of this
investigation, will be required to more definitively address this
possibility. Prior investigations have found comparable asso-
ciations between adherence to placebo study medication and
all-cause mortality. Following the publication of the original
Coronary Drug Project analysis
3, similar associations were
seen in several other studies
4–10. Two trials did not find this
association
18–20, though the latter was based on only nine
arrhythmic deaths. When these data were combined in a meta-
analysis, a strong association between placebo adherence and
total mortality was observed, with a summary odds ratio=0.56
(95% CI: 0.43 to 0.74)
11. Three studies examined non-mortality
endpoints: one did not find associations between placebo
adherence and CHD or stroke incidence
6, one did observe
associations with sudden cardiac death and cardiac mortality
9,
and another found an association with hospitalization for
CHF
10.
Several limitations to these analyses should be noted. First,
there were few psychosocial variables available for adjustment,
and these characteristics may be important determinants of
survival
21–25, though whether such variables are also associ-
ated with adherence, fulfilling the definition of confounding,
remains to be determined. Other, potentially important pre-
dictors of mortality in patients with CHF, such as exercise and
depression, were not available for analysis and, if associated
with adherence, may explain some of our findings. While the
overall quality of the data was high, 2–3% of individual visit
adherence values exceeded our data quality cutoff point and
were set to missing. Finally, the lack of longitudinal data on
potential confounders made it impossible to adjust for changes
in these risk factors during the trials.
The implications of these findings are profound. The
improved survivalassociatedwithgreateradherence toplacebo,
if validated in other studies, is substantial and clinically
meaningful. As noted, the factor(s) associated with this mortal-
ity reduction do not appear to be easily identifiable, but these
analyses suggest that this survival advantage is not associated
with risk factors that are commonly considered to predict
survival, including smoking, hyperlipidemia, hypertension,
and diabetes. Understanding for what placebo adherence is a
marker may shed important light on strong determinants of
health that go beyond traditional, well-accepted risk factors.
Whether such determinants are intrinsic personal character-
istics or represent potentially modifiable behaviors and psycho-
logical attributes that could be used to improve patients' health
outcomes is a critical issue that deserves greater investigation
and understanding.
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